Cargando…

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies

Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yutani, Shigeru, Shirahama, Takahisa, Muroya, Daisuke, Matsueda, Satoko, Yamaguchi, Rin, Morita, Michi, Shichijo, Shigeki, Yamada, Akira, Sasada, Tetsuro, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/
https://www.ncbi.nlm.nih.gov/pubmed/28622427
http://dx.doi.org/10.1111/cas.13301
_version_ 1783261064366915584
author Yutani, Shigeru
Shirahama, Takahisa
Muroya, Daisuke
Matsueda, Satoko
Yamaguchi, Rin
Morita, Michi
Shichijo, Shigeki
Yamada, Akira
Sasada, Tetsuro
Itoh, Kyogo
author_facet Yutani, Shigeru
Shirahama, Takahisa
Muroya, Daisuke
Matsueda, Satoko
Yamaguchi, Rin
Morita, Michi
Shichijo, Shigeki
Yamada, Akira
Sasada, Tetsuro
Itoh, Kyogo
author_sort Yutani, Shigeru
collection PubMed
description Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of PPV, further clinical studies of PPV would be warranted for patients with HCC refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the UMIN Clinical Trials Registry (UMIN000001882 and UMIN000003590).
format Online
Article
Text
id pubmed-5581512
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55815122017-09-06 Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies Yutani, Shigeru Shirahama, Takahisa Muroya, Daisuke Matsueda, Satoko Yamaguchi, Rin Morita, Michi Shichijo, Shigeki Yamada, Akira Sasada, Tetsuro Itoh, Kyogo Cancer Sci Original Articles Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre‐existing immunity. Twenty‐six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in cohort 1 and in 54% or 52% of patients in cohort 2, respectively. Successful IgG boosting at the end of the second cycle was observed in the majority of patients tested. Median overall survival was 18.7 months (95% confidence interval, 12.2–22.5 months) in cohort 1, and 8.5 months (95% confidence interval, 5.9–12.2 months) in cohort 2. Based on the higher rates of immune boosting and the safety profile of PPV, further clinical studies of PPV would be warranted for patients with HCC refractory to not only locoregional therapy but also both locoregional and systemic therapies. The protocol of this study was registered with the UMIN Clinical Trials Registry (UMIN000001882 and UMIN000003590). John Wiley and Sons Inc. 2017-07-23 2017-09 /pmc/articles/PMC5581512/ /pubmed/28622427 http://dx.doi.org/10.1111/cas.13301 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Yutani, Shigeru
Shirahama, Takahisa
Muroya, Daisuke
Matsueda, Satoko
Yamaguchi, Rin
Morita, Michi
Shichijo, Shigeki
Yamada, Akira
Sasada, Tetsuro
Itoh, Kyogo
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title_full Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title_fullStr Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title_full_unstemmed Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title_short Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
title_sort feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581512/
https://www.ncbi.nlm.nih.gov/pubmed/28622427
http://dx.doi.org/10.1111/cas.13301
work_keys_str_mv AT yutanishigeru feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT shirahamatakahisa feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT muroyadaisuke feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT matsuedasatoko feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT yamaguchirin feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT moritamichi feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT shichijoshigeki feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT yamadaakira feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT sasadatetsuro feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies
AT itohkyogo feasibilitystudyofpersonalizedpeptidevaccinationforhepatocellularcarcinomapatientsrefractorytolocoregionaltherapies